Personalis (NASDAQ:PSNL) Sees Large Volume Increase – Here’s What Happened

Personalis, Inc. (NASDAQ:PSNL) shares saw strong trading volume on Friday . 2,471,034 shares changed hands during mid-day trading, an increase of 124% from the previous session’s volume of 1,100,854 shares.The stock last traded at $10.2770 and had previously closed at $9.61.

Analysts Set New Price Targets

PSNL has been the topic of several analyst reports. Lake Street Capital reaffirmed a “buy” rating and set a $11.00 price target on shares of Personalis in a research note on Wednesday, November 5th. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Wednesday, October 8th. Morgan Stanley increased their target price on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Finally, Needham & Company LLC raised their target price on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.57.

Personalis Stock Up 6.5%

The business has a fifty day moving average of $8.79 and a 200 day moving average of $7.34. The firm has a market cap of $908.87 million, a P/E ratio of -11.63 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The company had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.31 million. On average, sell-side analysts expect that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Insider Buying and Selling at Personalis

In other news, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at approximately $1,772,857.24. This represents a 38.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher M. Hall sold 29,612 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $8.99, for a total value of $266,211.88. Following the transaction, the chief executive officer directly owned 148,486 shares in the company, valued at approximately $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Personalis

A number of large investors have recently made changes to their positions in the business. Royal Bank of Canada boosted its position in shares of Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares in the last quarter. Howland Capital Management LLC increased its stake in shares of Personalis by 0.9% in the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after purchasing an additional 2,500 shares in the last quarter. Legal & General Group Plc bought a new position in shares of Personalis in the second quarter worth about $30,000. Ameritas Investment Partners Inc. purchased a new stake in Personalis in the 2nd quarter worth about $34,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Personalis by 406.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the period. 61.91% of the stock is currently owned by institutional investors.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.